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Tsai et al.1 recently reported a retrospective study of 143
patients with surgically conﬁrmed necrotizing fasciitis (NF) in
southwest Taiwan. Although the authors concluded that hypoten-
sive shock, hypoalbuminemia, and increased banded leukocytes
were predictors of mortality, these risk factors necessitate
immediate surgical intervention. These indicators may reﬂect
the high severity of disease in these NF patients. Once NF isTable 1
Comparison of characteristics and mortality of necrotizing fasciitis survivors versus no
Characteristics Di
Male gender, n (%) 1
Age, years, median (IQR) 6
Age >60 years, n (%) 
Weight, kg, median (IQR) 10
Height, cm, median (IQR) 16
Body mass index, kg/m2, median (IQR) 3
Ethnicity, n (%)
Hawaiian and Paciﬁc Islander (Micronesia, Tonga, Samoa) 
Caucasian 
Asian 
Other (African-American, Hispanic) 
ICU admission, n (%) 1
Medical ICU 
Surgical ICU 
Amputation, n (%) 
APACHE II scores, median (IQR) 2
Time from admission to surgery, days, median (IQR) 
Length of hospitalization, days, median (IQR) 
Pathogen, positive culture, n (%)
Bacteremia, n (%) 
Polymicrobial 
Group A Streptococcus 
MRSA 
MSSA 
Gram-negative bacteria 
Anaerobes 
Positive wound culture, n (%) 1
Polymicrobial 
Group A Streptococcus 
MRSA 
MSSA 
Gram-negative bacteria 
Anaerobes 
Risk factors, n (%)
Diabetes mellitus 
Peripheral vascular disease 
Cancer 
Congestive heart failure 
NSAIDs 
Injection drug user 
History of immunosuppressant use <6 months 
History of surgery or trauma in previous 1 year 
IQR, interquartile range; ICU, intensive care unit; APACHE score, acute physiology and c
MSSA, methicillin-susceptible Staphylococcus aureus; NSAIDs, non-steroidal anti-inﬂam
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http://dx.doi.org/10.1016/j.ijid.2012.05.1021suspected, prompt surgical intervention should be performed. We
conducted a retrospective study at a major tertiary care hospital in
Hawaii between 1998 and 2005 to speciﬁcally examine the risk
factors and microbiology associated with mortality in histologi-
cally conﬁrmed NF.
One hundred and twenty NF cases were identiﬁed by ICD-9
code (rate of 75 cases/100 000 hospital admissions). Among 58
cases conﬁrmed by histopathology, the median age was 58 years;
69% were male and 36% Hawaiian/Paciﬁc Islanders. Demographic
information, bacteriology, co-morbidities, ethnicity, intensive caren-survivors
ed (n = 13) Survived (n = 45) p-Value
0 (76.9%) 30 (66.7%) 0.48
4 (10.5) 55 (19.0) 0.02
9 (69.2%) 15 (33.3%) 0.02
0 (34.1) 84 (30.8) 0.61
8 (4.5) 170 (15.2) 0.53
2.8 (12.6) 30.5 (8.5) 0.39
3 (23.1%) 14 (31.1%) 0.40
3 (23.1%) 13 (28.9%) 0.57
6 (46.2%) 15 (33.3%) 0.68
1 (7.6%) 3 (6.7%) 0.89
3 (100%) 28 (55.6%) <0.01
9 (69.2%) 8 (17.8%) <0.01
4 (30.8%) 20 (44.4%) 0.55
2 (15.4%) 5 (11.1%) 0.68
3.5 (10) 13 (9) 0.01
1 (3) 2 (1) 0.73
5 (8.5) 55 (40.0) <0.01
6 (46.2%) 15 (33.3%) 0.41
1 (7.7%) 3 (6.7%) 0.90
6 (46.2%) 7 (15.6%) 0.02
0 (0%) 1 (2.2%) 0.59
1 (7.7%) 2 (4.4%) 0.59
0 (0%) 5 (11.1%) 0.23
0 3 (6.7%) 0.33
1 (84.7%) 42 (93.3%) 0.32
7 (53.8%) 27 (60.0%) 0.69
7 (53.8%) 18 (40.0%) 0.38
1 (7.7%) 11 (24.4%) 0.19
2 (15.4%) 13 (28.9%) 0.33
6 (46.2%) 17 (37.8%) 0.59
2 (15.4%) 5 (11.1%) 0.68
5 (38.5%) 13 (28.9%) 0.51
3 (23.1%) 6 (13.3%) 0.39
2 (15.4%) 5 (11.1%) 0.68
5 (38.5%) 7 (15.6%) 0.07
3 (23.1%) 10 (22.2%) 0.95
1 (7.7%) 3 (6.7%) 0.89
1 (7.7%) 2 (4.4%) 0.64
4 (30.8%) 14 (31.1%) 0.98
hronic health evaluation score; MRSA, methicillin-resistant Staphylococcus aureus;
matory drugs.
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with the time from admission to surgery and the length of hospital
stay. These factors were compared between those who survived
and those who died (Table 1). An APACHE II score >17 was a
signiﬁcant independent predictor of mortality. The majority of NF
wound infections in our study were polymicrobial (58.6%), which is
different to the study of Tsai et al. and others.1–3
Group A Streptococcus (GAS) was also found to be associated
with higher mortality.4 Erdem et al.5 reported molecular epidemi-
ologic components of GAS in six NF patients (from two clusters of
fatal GAS skin infection in 1997 and 2002) and 116 community-
associated GAS infections in Hawaii in 2005. The results showed no
predominant emm types from NF patients (emm types 1, 12, 74, 99,
and 103), but emm type 64 was the most common type in GAS
isolated in Hawaii and this may account for the increased mortality
in Hawaii. Although Hawaii has a high prevalence of community-
associated methicillin-resistant Staphylococcus aureus (MRSA)
infections,6 our study did not show a high prevalence of MRSA
infection in NF compared to a study from California.7
The mortality rate of 22% in our cohort was signiﬁcantly
associated with GAS, age over 60 years, ICU admission, and
APACHE II score >17. Overall, the mortality of patients with NF was
related to patients with severe clinical diseases. Rapid detection
and regional differences in pathogens can provide additional
insight into severity and mortality risks. The prompt institution of
broad-spectrum antibiotics, surgical intervention, and intensive
support are essential for the effective management of NF patients.
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